Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2016

Publisher Name :
Date: 31-Aug-2016
No. of pages: 246
Inquire Before Buying

Global Markets Direct's, ‘Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2016', provides an overview of the Peripheral T-Cell Lymphomas (PTCL) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas (PTCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL)

  • The report reviews pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL) by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Peripheral T-Cell Lymphomas (PTCL) therapeutics and enlists all their major and minor projects

  • The report assesses Peripheral T-Cell Lymphomas (PTCL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Peripheral T-Cell Lymphomas (PTCL)

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Peripheral T-Cell Lymphomas (PTCL) pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Peripheral T-Cell Lymphomas (PTCL) Overview 10
Therapeutics Development 11
Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) - Overview 11
Peripheral T-Cell Lymphomas (PTCL) - Therapeutics under Development by Companies 12
Peripheral T-Cell Lymphomas (PTCL) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Peripheral T-Cell Lymphomas (PTCL) - Products under Development by Companies 17
Peripheral T-Cell Lymphomas (PTCL) - Companies Involved in Therapeutics Development 20
AB Science SA 20
Affimed GmbH 21
arGEN-X BV 22
Bayer AG 23
Boehringer Ingelheim GmbH 24
Celgene Corporation 25
CerRx, Inc. 26
Chipscreen Biosciences Ltd 27
CSPC Pharmaceutical Group Limited 28
Eisai Co., Ltd. 29
Genosco 30
Incyte Corporation 31
Japan Tobacco Inc. 32
Johnson & Johnson 33
Mundipharma International Ltd 34
Ono Pharmaceutical Co., Ltd. 35
Onxeo SA 36
Pfizer Inc. 37
Pharma Mar, S.A. 38
Portola Pharmaceuticals, Inc. 39
Rhizen Pharmaceuticals S.A. 40
Seattle Genetics, Inc. 41
Solasia Pharma K.K. 42
Spectrum Pharmaceuticals, Inc. 43
Peripheral T-Cell Lymphomas (PTCL) - Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Target 45
Assessment by Mechanism of Action 48
Assessment by Route of Administration 51
Assessment by Molecule Type 53
Drug Profiles 55
AFM-13 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
ARGX-110 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
belinostat - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
brentuximab vedotin - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Cellular Immunotherapy to Target CD7 for Relapsed and Refractory Leukemia and Lymphoma - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
cerdulatinib - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
copanlisib hydrochloride - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
darinaparsin - Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
denileukin diftitox - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
enasidenib - Drug Profile 110
Product Description 110
Mechanism Of Action 110
R&D Progress 110
fenretinide - Drug Profile 116
Product Description 116
Mechanism Of Action 116
R&D Progress 116
forodesine hydrochloride - Drug Profile 118
Product Description 118
Mechanism Of Action 118
R&D Progress 118
ICG-122 - Drug Profile 120
Product Description 120
Mechanism Of Action 120
R&D Progress 120
lenalidomide - Drug Profile 121
Product Description 121
Mechanism Of Action 121
R&D Progress 121
masitinib - Drug Profile 135
Product Description 135
Mechanism Of Action 135
R&D Progress 135
MEDI-570 - Drug Profile 149
Product Description 149
Mechanism Of Action 149
R&D Progress 149
mitoxantrone hydrochloride - Drug Profile 150
Product Description 150
Mechanism Of Action 150
R&D Progress 150
nivolumab - Drug Profile 152
Product Description 152
Mechanism Of Action 152
R&D Progress 152
NL-101 - Drug Profile 180
Product Description 180
Mechanism Of Action 180
R&D Progress 180
plitidepsin - Drug Profile 182
Product Description 182
Mechanism Of Action 182
R&D Progress 182
pralatrexate - Drug Profile 186
Product Description 186
Mechanism Of Action 186
R&D Progress 186
romidepsin - Drug Profile 192
Product Description 192
Mechanism Of Action 192
R&D Progress 192
RP-6530 - Drug Profile 195
Product Description 195
Mechanism Of Action 195
R&D Progress 195
ruxolitinib phosphate - Drug Profile 197
Product Description 197
Mechanism Of Action 197
R&D Progress 197
SH-7129 - Drug Profile 210
Product Description 210
Mechanism Of Action 210
R&D Progress 210
Small Molecule to Inhibit SYK for Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma - Drug Profile 211
Product Description 211
Mechanism Of Action 211
R&D Progress 211
temsirolimus - Drug Profile 212
Product Description 212
Mechanism Of Action 212
R&D Progress 212
TGR-1202 - Drug Profile 214
Product Description 214
Mechanism Of Action 214
R&D Progress 214
tipifarnib - Drug Profile 221
Product Description 221
Mechanism Of Action 221
R&D Progress 221
tucidinostat - Drug Profile 224
Product Description 224
Mechanism Of Action 224
R&D Progress 224
volasertib trihydrochloride - Drug Profile 227
Product Description 227
Mechanism Of Action 227
R&D Progress 227
Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects 231
Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products 232
Peripheral T-Cell Lymphomas (PTCL) - Product Development Milestones 233
Featured News & Press Releases 233
Aug 16, 2016: CAR T-cells Targeting the CD4 Protein Granted FDA Orphan Drug Designation 233
Aug 11, 2016: CAR T-cells Targeting the CD4 Protein Granted Orphan Drug Designation for the Treatment of Peripheral T-cell Lymphoma 233
Jun 14, 2016: PharmaMar Announces the Start of a Pivotal Study With plitidepsin in angioimmunoblastic T-cell lymphoma 234
Jun 02, 2016: Onxeo Announces Development of Beleodaq Oral Formulation Opening New Opportunities for Its HDAC Inhibitor 234
Mar 28, 2016: Solasia Initiates Phase 2 Study of Darinaparsin (SP-02) for Peripheral T-Cell Lymphoma 235
Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan 235
Dec 07, 2015: Seattle Genetics Highlights ADCETRIS Data Presentations in Frontline Non-Hodgkin Lymphoma at ASH 2015 236
Dec 06, 2015: Spectrum Pharmaceuticals and Onxeo Announce Complete Response in 67% of Patients with Peripheral T-Cell Lymphoma in Combination of Belinostat and Standard CHOP 238
Nov 09, 2015: Onxeo Reports Initial Results of Phase 1 Trial Evaluating Belinostat in Combination with CHOP in Peripheral T-cell Lymphoma 239
Sep 30, 2015: Kura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma 240
Jun 23, 2015: Beleodaq (belinostat) pivotal BELIEF study results published in the Journal of Clinical Oncology 241
May 27, 2015: AB Science: Phase 2 with masitinib in peripheral T-cell lymphoma accelerated into phase 3 241
Jan 12, 2015: HUYA Bioscience International Announces Regulatory Approval Of Chidamide, The First Selective HDAC Inhibitor In China 243
Jan 09, 2015: Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China 243
Jan 08, 2015: HUYA Bioscience International Is The First To Leverage Tripartite Cooperation 244
Appendix 245
Methodology 245
Coverage 245
Secondary Research 245
Primary Research 245
Expert Panel Validation 245
Contact Us 245
Disclaimer 246

List of Tables

Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Number of Products under Development by Companies, H2 2016 (Contd..1) 13
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Clinical Stage Development, H2 2016 15
Comparative Analysis by Early Stage Development, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Development by Companies, H2 2016 (Contd..1) 18
Products under Development by Companies, H2 2016 (Contd..2) 19
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by AB Science SA, H2 2016 20
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Affimed GmbH , H2 2016 21
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by arGEN-X BV, H2 2016 22
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Bayer AG, H2 2016 23
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 24
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Celgene Corporation, H2 2016 25
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by CerRx, Inc., H2 2016 26
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Chipscreen Biosciences Ltd, H2 2016 27
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 28
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Eisai Co., Ltd., H2 2016 29
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Genosco, H2 2016 30
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Incyte Corporation, H2 2016 31
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Japan Tobacco Inc., H2 2016 32
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Johnson & Johnson, H2 2016 33
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Mundipharma International Ltd, H2 2016 34
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 35
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Onxeo SA, H2 2016 36
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Pfizer Inc., H2 2016 37
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Pharma Mar, S.A., H2 2016 38
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Portola Pharmaceuticals, Inc., H2 2016 39
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016 40
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Seattle Genetics, Inc., H2 2016 41
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Solasia Pharma K.K., H2 2016 42
Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 43
Assessment by Monotherapy Products, H2 2016 44
Number of Products by Stage and Target, H2 2016 46
Number of Products by Stage and Mechanism of Action, H2 2016 49
Number of Products by Stage and Route of Administration, H2 2016 52
Number of Products by Stage and Molecule Type, H2 2016 54
Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects, H2 2016 231
Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products, H2 2016 232

List of Figures

Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 15
Comparative Analysis by Early Stage Products, H2 2016 16
Assessment by Monotherapy Products, H2 2016 44
Number of Products by Top 10 Targets, H2 2016 45
Number of Products by Stage and Top 10 Targets, H2 2016 45
Number of Products by Top 10 Mechanism of Actions, H2 2016 48
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 48
Number of Products by Routes of Administration, H2 2016 51
Number of Products by Stage and Routes of Administration, H2 2016 51
Number of Products by Molecule Types, H2 2016 53
Number of Products by Stage and Molecule Types, H2 2016 53
  • Global Circulating Tumor Cells Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 08-Dec-2016        Price: US 3480 Onwards        Pages: 110
    This report mainly covers Circulating Tumor Cells products, by types (CTC enrichment, CTC detection and CTC analysis), by applications (Prostate Cancer, Breast Cancer, Colorectal Cancer Diagnosis and Treatment and Others). Scope of the Report: This report focuses on the Circulating Tumor Cells in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, ty......
  • United States Non-small Cell Lung Cancer Therapeutics Market Report 2016
    Published: 01-Dec-2016        Price: US 3800 Onwards        Pages: 117
    Notes: Sales, means the sales volume of Non-small Cell Lung Cancer Therapeutics Revenue, means the sales value of Non-small Cell Lung Cancer Therapeutics This report studies sales (consumption) of Non-small Cell Lung Cancer Therapeutics in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Bristol-Myers Squibb - GlaxoSmithKline - Menarini - Sanofi - ZIOPHARM Onco......
  • Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 477
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016, provides an overview of the Refractory Acute Myeloid Leukemia (Oncology) pipeline landscape.The acute myeloid leukemia cells which resist treatment are referred to as refractory acute myeloid leukemia. Signs and symptoms includes pale skin, swollen gums, minor infections, such as perianal sores, loss of appetite and weight loss and aches or discomfo......
  • Small-Cell Lung Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 588
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Small-Cell Lung Cancer - Pipeline Review, H2 2016, provides an overview of the Small-Cell Lung Cancer (Oncology) pipeline landscape.Small cell lung cancer (SCLC) is a fast-growing type of lung cancer. It spreads much more quickly than non-small cell lung cancer. SCLC is the most aggressive form of lung cancer. It usually starts in the breathing tubes (bronchi) in the center of the chest. These tumors often spr......
  • Gallbladder Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 74
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H2 2016, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history, gallstones, gender and choledochal cysts......
  • Vaginal Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 68
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Cancer - Pipeline Review, H2 2016, provides an overview of the Vaginal Cancer (Oncology) pipeline landscape.Vaginal cancer is a rare cancer that occurs in vagina. Symptoms includes watery vaginal discharge, a lump or mass in vagina, painful urination, constipation and pelvic pain, vaginal bleeding. Risk factors include age, Smoking, HIV infection and vaginal intraepithelial neoplasia. Treatment include......
  • Epithelial Ovarian Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 507
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epithelial Ovarian Cancer - Pipeline Review, H2 2016, provides an overview of the Epithelial Ovarian Cancer (Oncology) pipeline landscape.Ovarian epithelial cancer is a disease in which malignant (cancer) cells form in the tissue covering the ovary. Early ovarian cancer may not cause any symptoms. When symptoms do appear, ovarian cancer is often advanced. Symptoms may include pain or swelling in the abdomen, p......
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 463
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016, provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) pipeline landscape.Metastatic hormone refractory prostate cancer (mHRPC), also known as metastatic androgen independent prostate cancer or metastatic castrate-resis......
  • Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 108
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016, provides an overview of the Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline landscape.Muscle-invasive disease is a type of bladder cancer which is much more likely to spread to other parts of the body Symptoms includes blood in the urine and pain when passing urine. Risk factors include use of tobacco, family history, exposure to arsen......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs